Home Featured Page 148

Featured

Latest

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

PT338 – Melissa Lavasani – The Power of Storytelling, The Preservation...

George Tziras to Succeed Peter Rands as Small Pharma Chief...

Small Pharma Reports Fiscal First Quarter 2023 Highlights

FILAMENT HEALTH ANNOUNCES CLOSING OF $2,500,080 PRIVATE PLACEMENT

Numinus Wellness Inc. Reports Q3 2022 Results

Psychedelic Bulletin #111 – Psychedelics on Netflix; House Adopts 2 Psychedelic...

MDMA: Rolling from Counterculture to the Clinic Counter

PT337 – Lauren Katalinich & Anya Oleksiuk – The Psychedelic Society:...

Silo Pharma Announces Positive Results in Subcutaneous Delivery of its Novel...

Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And...

1...147148149...292 Page 148 of 292

EDITOR PICKS

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

PT338 – Melissa Lavasani – The Power of Storytelling, The Preservation...

George Tziras to Succeed Peter Rands as Small Pharma Chief...

Small Pharma Reports Fiscal First Quarter 2023 Highlights

FILAMENT HEALTH ANNOUNCES CLOSING OF $2,500,080 PRIVATE PLACEMENT

Numinus Wellness Inc. Reports Q3 2022 Results

Psychedelic Bulletin #111 – Psychedelics on Netflix; House Adopts 2 Psychedelic...

MDMA: Rolling from Counterculture to the Clinic Counter

PT337 – Lauren Katalinich & Anya Oleksiuk – The Psychedelic Society:...

Silo Pharma Announces Positive Results in Subcutaneous Delivery of its Novel...

Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And...

EDITOR PICKS

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY